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Ubiquitin modification is a well established way of
regulating protein levels and activities. Modification by
related ubiquitin-like proteins is turning out to have a
diverse range of interesting cellular functions.
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A cell must control the concentrations of its proteins to
survive. The rates of synthesis and degradation of function-
ally critical proteins need to be tightly regulated so that the
right concentrations of active molecules are present at the
right times. The cell also needs a way of removing specific
proteins; for example, cell-cycle progression requires the
degradation of cyclin-dependent kinase inhibitors. This
process must be carried out efficiently and quickly, and be
highly specific. One way of achieving such regulation uses a
remarkable molecule called ubiquitin and is known as the
ubiquitin-dependant protein degradation pathway. Recent
studies have identified a family of proteins related to ubiq-
uitin, which are also turning out to have intriguing roles in
cellular regulation — though not by targeted proteolysis.
Ubiquitin is an abundant and highly conserved 76 residue
protein, that can exist in cells either as a free monomer or
covalently attached to other protein molecules [1]. This
covalent modification is required for a variety of processes,
including endocytosis, protein targeting to the endosome
and the activation of IκBα protein kinase, but its major
functional role is in targeting proteins for degradation by
the 26S proteasome. Ubiquitin is attached to its target
protein via a multi-enzyme ATP-dependent pathway,
which results in formation of an isopeptide bond between
the ε-amino group of the substrate lysine residue and the
carboxyl terminus of ubiquitin (Figure 1). The modification
reaction is dependent on ubiquitin’s conserved carboxy-ter-
minal sequence arginine–glycine–glycine.
The first step in the pathway is the ATP-dependent
formation of a thioester bond between the carboxy-terminal
glycine of ubiquitin and the active site cysteine within the
ubiquitin activating enzyme E1. Ubiquitin monomers are
then transferred to one of several ubiquitin-conjugating
(Ubc) E2 enzymes by transesterification. A third enzyme,
E3, is sometimes required, and can be either a single protein
or a multiprotein complex. E2 and E3 determine the 
substrate recognition and specificity of ubiquitination. 
Ubiquitin is then transferred to its target protein and the
process repeated, producing a polyubiquitin chain, usually
linked via lysine 48. As monoubiquitinated proteins are not
degraded, it is likely that polyubiquitin chains act as recogni-
tion signals for the 26S proteasome (Figure 1); mutant ubiq-
uitin molecules that cannot be further ubiquitinated actually
inhibit proteolysis [1]. The polyubiquitin chains are cleaved
from the tagged proteins and disassembled after docking at
the proteasome, but before degradation of the target protein.
Figure 1
Pathways for modification by ubiquitin and ubiquitin-like proteins. Target
protein modification by ubiquitin requires enzymes E1, E2 and sometimes
E3, and results in formation of an isopeptide bond between ubiquitin and
the target protein. Subsequent ubiquitin molecules can be added on to
ubiquitin itself; the resulting polyubiquitinated protein is then degraded by
the 26S proteasome, and the ubiquitin recycled for further modification
cycles. The SUMO-1 and Rub1 modification pathways are similar to the
ubiquitin pathway, but require their own enzymes and only single
molecules appear to be attached to target proteins. SUMO-1 and Rub1
modification is not directly linked to proteolysis, but appears to alter the
stability and/or localisation of the target protein (see text for details).
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There have been a number of recent reports of proteins
similar in sequence to ubiquitin, termed ubiquitin-like
proteins, that can also form covalent conjugates. These
ubiquitin-like modifications have many mechanistic
similarities with the ubiquitin pathway, but surprisingly
they do not appear to be linked to proteolysis. In
particular, the two ubiquitin-like proteins SUMO-1 and
NEDD8, and their respective counterparts in the budding
yeast Saccharomyces cerevisiae, Smt3 and Rub1, have
recently attracted considerable attention and appear to
have interesting roles in cellular regulation. 
SUMO-1 — for ‘small ubiquitin-like modifier’ — is a
small protein that shows only limited sequence similarity
to ubiquitin, but does have the conserved carboxy-termi-
nal sequence glycine–glycine. As SUMO-1 was discovered
independently by several groups, it has a plethora of alter-
native names, including PIC1, UBL1, GMP1, Sentrin and
SMT3C [2]. SUMO-1 can covalently modify a large
number of proteins, of which four have been identified so
far; these target proteins, RanGAP1, PML, Sp100 and
IκBα [3–7], are considered in more detail below. Like
ubiquitin, SUMO-1 is synthesised as a precursor —
SUMO-1 has a four residue carboxy-terminal tail that is
cleaved off to generate the activate form of the protein [8].
Conjugation of SUMO-1 to target proteins is also ATP-
dependent and requires E1 and E2 enzymes; an equiva-
lent of ubiquitin’s lysine 48 is lacking, however, so
poly-SUMO-1 chains probably cannot be formed. 
Does SUMO-1 use the same conjugation enzymes as ubiq-
uitin? The sequence divergence of SUMO-1 from ubiquitin
would suggest not, and this is indeed the case. The E1
enzyme for the yeast homologue Smt3, and presumably also
for mammalian SUMO-1, is a heterodimer [9]. One subunit,
Uba2, is similar in sequence to a carboxy-terminal part of
the ubiquitin E1, and contains the active cysteine which
forms the thioester with Smt3. The other subunit, Aos1, is
similar to the remaining amino-terminal part of ubiquitin
E1. An E2 enzyme for SUMO-1/Smt3, Ubc9, is essential for
cell-cycle progression and was initially thought to conjugate
ubiquitin. Ubc9 turns out to be specific for SUMO-1/Smt3,
and uses the E2 conserved active-site residue, cysteine 93,
for thioester formation [10–12]. Importantly, conjugation of
SUMO-1 to RanGAP1 has an absolute requirement for
Ubc9 [12]. Ubc9 also interacts with both IκBα and PML in
yeast, and seems likely to be the conjugating enzyme for all
SUMO-1/Smt3 modifications.
The first identified SUMO-1 target was the Ran GTPase-
activating protein RanGAP1, which appears to be the
major SUMO-1 substrate in mammalian cells [3,4]. Ran is
a small GTPase of the Ras superfamily, which plays an
essential part in nucleocytoplasmic transport. GTP
hydrolysis by Ran sustains active nuclear import and
export. RanGAP1, which activates the GTPase activity of
Ran, is localised predominantly at the nuclear envelope,
where it forms a stable complex with the nuclear-pore-
complex protein RanBP2/Nup358 [13]. This interaction
requires covalent addition of SUMO-1 to RanGAP1 at
lysine 526 [8,13]. This modification alone is not sufficient
for nuclear-pore-complex binding, however, as a SUMO-
1-modified fusion protein containing the carboxyl termi-
nus of RanGAP1 localises to the nucleus, and not to the
nuclear pore complex. Covalent attachment of SUMO-1
to RanGAP1 might expose or create a new site for
Nup358 binding [13].
An intriguing new paper by Desterro et al. [14] reports that
SUMO-1 can also modify IκBα, the inhibitor of NF-κB.
NF-κB is a transcription factor that plays a key role in reg-
ulating the inducible expression of a number of genes,
particularly those involved in immune and inflammatory
responses [15]. The transcriptional activity of NF-κB is
primarily controlled by a signalling pathway which affects
the intracellular localisation of NF-κB (Figure 2). Inactive
NF-κB exists in a cytoplasmic complex with its inhibitor
IκBα. Upon stimulation by various factors, such as
cytokines or stress, IκBα is phosphorylated and then
degraded by the ubiquitin-dependent pathway (Figure 2).
This allows NF-κB to translocate to the nucleus, bind to
specific DNA target sequences and activate transcription.
Interestingly, as part of an autoregulatory loop, NF-κB
also activates IκBα transcription and newly made IκBα
transiently accumulates in the nucleus, where it mediates
the transport of the inactive NF-κB–IκBα complex back
to the cytoplasm (Figure 2). 
Desterro et al. [14] found that the non-phosphorylated, but
not the phosphorylated, form of IκBα can be modified by
SUMO-1, and that the modified form is resistant to signal-
induced degradation. The most extraordinary feature of
the SUMO-1 modification of IκBα is that the same lysine
residue is conjugated by either SUMO-1 or ubiquitin
(Figure 2). SUMO-1-modified IκBα cannot be ubiquiti-
nated and would therefore be resistant to proteasomal
degradation. In support of this idea, Desterro et al. [14]
demonstrated that SUMO-1 expression inhibits NF-κB-
dependent transcription and that the modification of IκBα
by SUMO-1 is inhibited by phosphorylation. This strongly
points to SUMO-1 playing a major role in regulating the
transcriptional activity of NF-κB, further illustrating the
cellular importance of SUMO-1 modification.
The two other identified proteins that have been found to
be subject to modification by SUMO-1, promyelocytic
leukaemia protein (PML) and Sp100 [6,7,16], are both
found in large nuclear multi-protein complexes known as
‘PML nuclear bodies’ [17]. Unlike RanGAP1 and IκBα,
multiple conjugates of PML with SUMO-1 have been
seen, probably resulting from the conjugation by SUMO-1
on several lysine residues [5]. The SUMO-1 modification
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appears to be important for the intranuclear compartmen-
talisation of PML and Sp100 — unmodified PML and
Sp100 localise to the soluble nucleoplasm and cytoplasm,
respectively, whereas SUMO-1-modified PML and Sp100
partition to the insoluble nuclear matrix PML nuclear
bodies [5,6]. It is tempting to speculate that a dynamic
equilibrium exists between these two states, although it
remains to be determined which is biologically relevant,
and what cellular signals regulate this partitioning.
What are the functions of SUMO-1 modification? A
couple of main themes are emerging from these recent
studies. One is that, like ubiquitin, SUMO-1 plays a major
role in targeting protein molecules to particular subcellular
compartments. This is true of RanGAP1, the modified
form of which is targeted to nuclear pore complexes, and
perhaps true of PML and Sp100, modified forms of which
are partitioned to PML nuclear bodies. Another plausible
role for SUMO-1 is in the regulation of ubiquitin-medi-
ated proteolysis, as in the case of IκBα. The modification
of the same lysine residue on a target protein by either
SUMO-1 or ubiquitin means that SUMO-1 addition can
block ubiquitin attachment and thus ubiquitin-dependent
proteolysis. This competition may not occur with all sub-
strates, but perhaps only to a small number of proteins
that require an extra level of regulation. The identification
of further SUMO-1 target proteins will greatly help our
future understanding of SUMO-1 function.
Another recently identified ubiquitin-like protein is Rub1
— for ‘related to ubiquitin 1’ — which was initially identi-
fied through the yeast genome project [18] and is the func-
tional orthologue of NEDD8, a developmentally regulated
human protein [19]. Rub1 and NEDD8 are the closest rel-
atives of ubiquitin identified so far. Both have the con-
served carboxy-terminal arginine–glycine–glycine motif
and the lysine residue that in ubiquitin provides the link
for polyubiquitination. Both can also covalently modify a
number of nuclear proteins, though there appear to be
fewer target proteins for Rub1/NEDD8 than for ubiquitin
and SUMO-1 [20–22]. E1 and E2 enzymes specific for
Rub1 have been identified. The Rub1 E1 is a heterodimer
of Enr2, also known as Ula1, and Uba3. Enr2  and Uba3
are similar to amino-terminal and carboxy-terminal parts,
respectively of ubiquitin E1. The Rub1 E2 enzyme is
Ubc12; it is not known whether an E3 enzyme is involved
in Rub1 modification [22].
What are the targets for Rub1 modification? Two recent
papers have reported that Rub1 covalently modifies
Cdc53 [21,22], a protein required for G1–S cell-cycle
progression in S. cerevisiae. Cdc53 is a component of a
ubiquitin ligase complex — an E3 enzyme — that
catalyses the addition of ubiquitin to a variety of target
proteins using substrate-specific ‘adaptors’. The adaptors
are so-called F-box proteins; one such F-box adaptor is
Cdc4, which directs specific degradation of the cyclin-
dependent kinase inhibitor Sic1. The mammalian
homologue of Rub1, NEDD8, has recently been shown to
conjugate to cullin-4A, which is related to Cdc53 [23]. The
involvement of Cdc53 in both the Rub1 and ubiquitin
modification pathways raises the interesting question of
whether there is interplay between the two systems. Rub1
might alter the substrate specificity of the ubiquitin ligase
complex or affect the partitioning of Cdc53 to different
complexes. Alternatively, Rub1 conjugation might simply
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Figure 2
Activation of NF-κB and the role of SUMO-1
modification. Phosphorylation of the NF-κB
inhibitor IκBα triggers its polyubiquitination
and degradation, allowing NF-κB, a p50–p65
heterodimer, to translocate to the nucleus and
activate transcription of specific genes,
including that for its inhibitor IκBα. SUMO-1
modification of non-phosphorylated IκBα
prevents ubiquitin attachment, thus inhibiting
NF-κB activation. The other known SUMO-1
target proteins — RanGAP1, PML and Sp100
— are also shown.
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be required for optimal assembly of the ubiquitin ligase
complex. It appears unlikely that Rub1 modification has
an essential role in cell-cycle regulation, as rub1, uba3, enr2
or ubc12 deletions leave yeast surprisingly healthy.
There are clearly many parallels between the ubiquitin
and ubiquitin-like conjugation systems, although ubiqui-
tin-like modifiers appear to act on a more specialised set of
substrates than ubiquitin itself. It is difficult at present to
know whether there is a general function for all ubiquitin-
like modifications. SUMO-1 and Rub1 both appear to act
in a way that is connected with ubiquitin-dependent
protein degradation, although modification by SUMO-1
and Rub1 per se does not alter the stability of their respec-
tive target proteins. Could ubiquitin-like modification act
as general inhibitor of ubiquitin-dependent proteolysis?
This cannot be answered yet from available data, but it is
an attractive theory. Ubiquitin-like modification might
provide an additional, dynamic way of regulating protein
concentration in the cell. Such modifications might be
reversible, for example by cleavage with specific hydro-
lases. The ubiquitin-specific hydrolase HAUSP, which
localises to PML nuclear bodies but does not hydrolyse
SUMO-1-modified conjugates, may promote SUMO-1
modification by cleavage of ubiquitin from ubiquitin–PML
conjugates, allowing conjugation by SUMO-1 instead [24].
Do ubiquitin-like modifications regulate the cell cycle? It
is known that the E2 enzyme Ubc9 is essential for pro-
gression from G2 to early M phase, but it is unable to form
a thioester with ubiquitin and is specific for SUMO-1.
The implication is that SUMO-1 modifications are essen-
tial for cell-cycle progession. The modification of Cdc53
by Rub1 also points towards a link to cell-cycle regulation,
as Cdc53 is required for G1–S progression. The obvious
speculation would be that these ubiquitin-like modifica-
tions stabilise cell-cycle control proteins, perhaps tran-
siently, before they are actively degraded.
Another recurring theme is that the subcellular localisation
of a target protein is often affected by ubiquitin-like modifi-
cation. SUMO-1 appears to be involved in nuclear or perin-
uclear targeting, and another ubiquitin-like family member,
UCRP — ‘ubiquitin cross-reactive protein’, also known as
ISG15 — has been reported to target substrates to the
cytoskeleton [25]. Ubiquitin-like modifications may not
only inhibit ubiquitin-mediated degradation, but also relo-
calise target proteins. Whether there is a common function
for all ubiquitin-like modifications is not clear. One thing
that is clear, however, is that the ubiquitin-like modification
field is advancing rapidly and it will not be long before we
have answers to all of these and other interesting questions.
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